title: Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes.
abstract: The administration of the omega-3 fatty acid eicosapentaenoic acid (EPA) to a drug-naive patient with schizophrenia, untreated with conventional antipsychotic medication, led to a dramatic and sustained clinical improvement in both positive and negative symptoms. This was accompanied by a correction in erythrocyte membranes of abnormalities in both n-3 and n-6 highly unsaturated fatty acids and with reduced neuronal membrane phospholipid turnover, as evidenced by serial 31-phosphorus cerebral magnetic resonance spectroscopy. Using recently developed techniques of image segmentation, subvoxel registration and quantitation, analysis of serial high-resolution 3D cerebral MRI scans showed that, in the year before EPA treatment, cerebral atrophy was taking place and that this atrophy was reversed by six months of EPA treatment. These results demonstrate that EPA can reverse both the phospholipid abnormalities previously described in schizophrenia and cerebral atrophy. They provide strong further evidence in support of the membrane phospholipid model of schizophrenia.
authors.affiliation: MRI Unit, Hammersmith Hospital, London, UK.
authors.forename: B K
authors.initials: BK
authors.lastname: Puri
authors.forename: A J
authors.initials: AJ
authors.lastname: Richardson
authors.forename: D F
authors.initials: DF
authors.lastname: Horrobin
authors.forename: T
authors.initials: T
authors.lastname: Easton
authors.forename: N
authors.initials: N
authors.lastname: Saeed
authors.forename: A
authors.initials: A
authors.lastname: Oatridge
authors.forename: J V
authors.initials: JV
authors.lastname: Hajnal
authors.forename: G M
authors.initials: GM
authors.lastname: Bydder
mesh_terms: D000328:Adult; D001095:Arachidonic Acids / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001927:Brain Diseases / Q000473:pathology*; D004281:Docosahexaenoic Acids / Q000097:blood; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D004910:Erythrocyte Membrane / Q000737:chemistry / Q000187:drug effects*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D010743:Phospholipids / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D001095:Arachidonic Acids; D015415:Biomarkers; D010743:Phospholipids; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid